Cite
HARVARD Citation
Moore, M. et al. (n.d.). Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy. Annals of oncology. pp. 2216-2224. [Online].